<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363350</url>
  </required_header>
  <id_info>
    <org_study_id>METc2005.229</org_study_id>
    <nct_id>NCT00363350</nct_id>
  </id_info>
  <brief_title>Rituximab Treatment in Sjogren's Syndrome</brief_title>
  <official_title>Rituximab for the Treatment of Primary Sjögren's Syndrome: a Double Blinded Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <brief_summary>
    <textblock>
      This study is an evaluation of the effect of rituximab compared to placebo in combination
      with steroids on salivary flow and serological and clinical parameters in patients with
      primary SS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      phase II trial

      Study objective:

      evaluation of the effect of rituximab compared to placebo in combination with steroids on
      salivary flow and serological and clinical parameters in patients with primary SS

      Number of participating centres:

      1

      Duration:

      follow-up 48 weeks

      Study medication:

      2 infusions on day 1 and day 15 rituximab infusions (1000 mg) or placebo infusions
      intravenous infusion of 100 mg of methylprednisolone before infusion of rituximab (or the
      placebo for rituximab), together with 60 mg per day of oral prednisone on days 2, 3, 16 and
      17, 30 mg per day on days 4, 5, 18 and 19 and 15 mg per day on days 6 and 20

      Primary objective/endpoint:

      stimulated salivary gland function (stimulated submandibular/sublingual and parotid saliva)

      Secondary objectives/endpoint:

      Functional parameters Laboratory parameters Subjective parameters Histological/Molecular
      parameters

      Number of subjects:

      30 patients with primary SS (20 patients rituximab treatment, 10 patients placebo)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stimulated whole salivary flow rate</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional parameters</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective parameters</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological/Molecular parameters</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab (anti-CD20)</intervention_name>
    <description>2 infusions of 1000 mg</description>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stimulated whole saliva secretion ≥ 0,15 ml/min

          -  Male or female &gt; 18 years

          -  Primary SS according to the revised European - U.S. criteria(22)

          -  Positive autoantibodies (IgM-Rf &gt; 10 and SS-A and/or SS-B)

          -  Parotid gland biopsy (paraffine material and fresh frozen tissue) with characteristic
             features of SS performed at time of inclusion (no longer than 12 months ago)

          -  Use of reliable method of contraception during the study

          -  Written informed consent

        Exclusion Criteria:

          -  The presence of any other connective tissue disease

          -  Preceding treatment with anti-TNF or other monoclonal antibodies

          -  Use of prednisone, hydroxychloroquine less than 1 month ago

          -  Use of MTX, cyclophosphamide, cyclosporin, azathioprine and other DMARDS less than 0,5
             year ago

          -  Serum creatine &gt; 2.8 mg/dl (250 micromol/l)

          -  ASAT or ALAT outside 1.5 x upper normal range of the laboratory

          -  Hb &lt; 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females

          -  Neutrophil granulocytes less than 0.5 x 109/l

          -  Platelet count less then 50 x 109/l

          -  Positive pregnancy test or breast-feeding

          -  History of alcohol or drug abuse

          -  Serious infections

          -  Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions,
             chronic or latent infectious diseases or immune deficiency which places the patient at
             an unacceptable risk for participation in the study

          -  History of any malignancy with the exception of completely resected basal cell
             carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiska Meijer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 2005 Sep;52(9):2740-50.</citation>
    <PMID>16142737</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2006</study_first_submitted>
  <study_first_submitted_qc>August 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>February 23, 2009</last_update_submitted>
  <last_update_submitted_qc>February 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>H Bootsma</name_title>
    <organization>University Medical Centre Groningen</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

